Aktienanalyse zu CorMedix Inc (CRMD)CRMDCorMedix Inc

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CorMedix Inc (CRMD) is a good buy right now due to its recent strong financial performance, including a Q2 revenue of $101.9 million, which is a significant increase from $39.7 million a year ago, and a gross margin of 75.66%. Additionally, analysts have set a price target of $14, suggesting a 59.27% upside from the current price of $8.3. The main risk is the year-to-date change of -31.74%, indicating volatility in the stock's performance.

1 analysts cover CRMD: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 13.67.